Author

Andrew Goldwin

Observed institution: AstraZeneca (United Kingdom)

OpenAlex ID: A5041014338

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

2021 · Timothy A. Yap, Matthew G. Krebs, et al. · Clinical Cancer Research · 132

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.

2023 · Kristoffer Staal Rohrberg, Mariana Brandão, et al. · Journal of Clinical Oncology · 23

Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts

2021 · Emma Dean, Matthew G Krebs, et al. · Cancer Research · 4

Supplementary Data from Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

2024 · Timothy A. Yap, Matthew G. Krebs, et al.

Data from Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

2024 · Timothy A. Yap, Matthew G. Krebs, et al.

Works count: 5

Citation count: 159

H-index: 3

I10-index: 2